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ABSTRACT
Sensitivity of cancer cells to DNA damaging chemotherapeutics is determined 
by DNA repair processes. Consequently, cancer cells may upregulate the expression 
of certain DNA repair genes as a mechanism to promote chemoresistance. Here, 
we report that RECQ1, a breast cancer susceptibility gene that encodes the most 
abundant RecQ helicase in humans, is a p53-regulated gene, potentially acting as 
a defense against DNA damaging agents. We show that RECQ1 mRNA and protein 
levels are upregulated upon treatment of cancer cells with a variety of DNA damaging 
agents including the DNA-alkylating agent methylmethanesulfonate (MMS). The MMS-
induced upregulation of RECQ1 expression is p53-dependent as it was observed in 
p53-proficient but not in isogenic p53-deficient cells. The RECQ1 promoter is bound 
by endogenous p53 and is responsive to p53 in luciferase reporter assays suggesting 
that RECQ1 is a direct target of p53. Treatment with the chemotherapeutic drugs 
temozolomide and fotemustine also increased RECQ1 mRNA levels whereas depletion 
of RECQ1 enhanced cellular sensitivity to these agents. These results identify a 
previously unrecognized p53-mediated upregulation of RECQ1 expression in response 
to DNA damage and implicate RECQ1 in the repair of DNA lesions including those 
induced by alkylating and other chemotherapeutic agents.
INTRODUCTION
Genes encoding proteins that function in replication 
checkpoint, maintenance of stalled replication forks 
and homologous recombination repair are frequently 
upregulated in a variety of cancers [1–3]. The upregulation 
of these genes in highly proliferative cancer cells is believed 
to be a general adaptive response to chronic replication 
stress, activating replication origins to compensate for 
DNA replication fork stalling and inducing DNA repair to 
cope with chromosomal breakage. However, increase in the 
expression of regulatory proteins of DNA damage-sensing 
and repair pathways contribute to improved DNA repair 
capacity, increased DNA damage tolerance, and the failure 
of cell death pathways. Consequently, upregulation of DNA 
repair genes is a mechanism to promote chemoresistance in 
tumor cells [3]. 
The RecQ helicases, described as caretakers of 
the genome, contribute multiple catalytic activities to 
DNA replication, repair, transcription, and telomere 
maintenance [4–6]. In humans, functional defects in 
RecQ proteins predispose to cancer. At the cellular level, 
loss of their functions leads to increased DNA damage, 
genomic instability and enhanced sensitivity to a variety 
Oncotarget2www.impactjournals.com/oncotarget
of chemotherapeutic agents. The tumor suppressor roles of 
RecQ proteins are mediated through their genome caretaker 
roles; and the evidence that RecQ proteins directly regulate 
tumorigenesis is scarce. The elevated expression of RecQ 
helicases in rapidly proliferating cells and in many human 
cancers suggests possible roles in resistance to DNA-
damaging agents and their expression levels may predict 
the responsiveness of cancers to certain chemotherapeutic 
agents [4]. However, whether or not RecQ helicases are 
regulated at the mRNA and/or protein level to provide 
cellular protection against genotoxic stress is poorly known 
[7]. 
Here we wanted to investigate whether DNA 
damage modulates the expression of RECQ1, a RecQ 
family member critical for DNA repair mechanisms that 
restore productive replication following stress and prevent 
genomic instability [8]. RECQ1 (also known as RECQL 
or RECQL1) was recently identified as a breast cancer 
susceptibility gene [9, 10]. Previous studies have shown 
that RECQ1 is upregulated in rapidly dividing cells and its 
expression is higher in many cancer cell lines as compared 
to normal cells [11]. Furthermore, RECQ1 silencing 
reduces proliferation of cancer cells and suppresses tumor 
growth in mouse xenograft models [12, 13]. RECQ1 can 
contribute to tumor development and progression by 
regulating the expression of key genes that promote cancer 
cell migration, invasion and metastasis [14, 15]. Indeed, 
RECQ1 is frequently over-expressed and amplified in 
many cancer samples (http://www.cbioportal.org/public-
portal); and altered RECQ1 expression is correlated 
with patient’s response to therapy [16–20]. Consistent 
with this, suppression of RECQ1 expression in mice and 
human cells is manifested as constitutively elevated sister 
chromatid exchange, chromosomal breakage, and increased 
sensitivity to ionizing radiation [21, 22]. RECQ1 is critical 
for telomere maintenance [23, 24], restores replication fork 
progression following stress [25–27], participates in DNA 
double strand break repair [28], responds to oxidative DNA 
damage [29, 30], and performs a mechanistic role in base 
excision repair (BER) pathway which removes chemical 
alterations to DNA bases such as oxidation and alkylation 
[31]. Thus, we hypothesized that overexpression of RECQ1 
may provide a survival advantage to cancer cells by 
promoting the ability of cancer cells to tolerate genotoxic 
stress. 
Herein, we demonstrate that RECQ1, the gene 
encoding the most abundant RecQ family protein in 
humans, is upregulated upon DNA damage in a p53-
dependent manner. These results provide novel insight 
into regulation of RECQ1 expression and its role in 
DNA damage response. As RECQ1 efficiently protects 
cells from genomic instability through repair of DNA 
lesions including those induced by alkylating and other 
chemotherapeutic agents, elevated RECQ1 expression in 
tumor cells may provide resistance to anticancer drugs. 
RESULTS
Genotoxic stress upregulates RECQ1 expression 
To test whether genotoxic stress modulates RECQ1 
expression, we first measured RECQ1 mRNA levels in 
U2OS (osteosarcoma) cells that were either untreated or 
treated with etoposide (1 µM), doxorubicin (500 nM) or 
methylmethanesulfonate (MMS, 1 mM) for 4, 8 or 24 h 
(Figure 1A). Quantitative RT-PCR (qRT-PCR) analysis 
demonstrated increased RECQ1 mRNA levels (2- to 8-fold) 
in response to these treatments. The kinetics and magnitude 
of the induction varied for each genotoxic agent. For 
etoposide and doxorubicin, highest level of RECQ1 mRNA 
was observed after 24 h (Figure 1A). As compared to 
untreated cells, U2OS cells grown for 24 h in the presence 
of etoposide and doxorubicin displayed about 3- and 8-fold 
increase in RECQ1 mRNA, respectively. Treatment with 
MMS however resulted in an early induction of RECQ1 
mRNA and ~5-fold increase was observed at 4 h following 
MMS treatment (Figure 1A). In contrast to RECQ1 
mRNA, these treatments did not change β-actin mRNA 
levels. The MMS (1 mM, 4 h) triggered upregulation of 
RECQ1 mRNA (3- to 5-fold) was also observed in mouse 
embryonic fibroblasts (Figure 1B). Treatment with MMS (1 
mM, 4 h) also resulted in a significant increase > 2.5-fold 
(p < 0.05) in RECQ1 mRNA in MCF7 cells (breast cancer) 
similar to U2OS cells but not in HeLa (cervical carcinoma) 
cells (Figure 1C). 
An important factor involved in transcriptional 
regulation of genes after DNA damage is p53, which 
becomes activated by the ATM/ATR pathway upon DNA 
damage [32]. Analysis of RECQ1 mRNA levels in U2OS 
cells treated with MMS indicated a correlation with 
induction of the canonical p53 target p21 (CDKN1A) 
suggesting that p53 status may influence DNA damage 
triggered upregulation of RECQ1 (Figure 1C). Treatment 
of cells with MMS activates ATM by single strand breaks 
arising during the repair of alkylating DNA lesions [33]. 
Similarly, DNA-PK has also been implicated in MMS 
mediated DNA damage response [34]. To test whether 
DNA-damage triggered increase in RECQ1 expression 
requires activities of ATM and DNA-PK, we measured 
RECQ1 mRNA in U2OS cells in the presence of 
pharmacological inhibitors of ATM (ATMi, Ku55933) or 
DNA-PK (DNA-PKi, Nu7026) prior to MMS exposure. 
Incubation of U2OS cells with ATMi or DNA-PKi (10 µM, 
16 h) alone resulted in about 2-fold increase in RECQ1 
mRNA (Figure 1D) perhaps due to increased DNA damage 
load upon inhibiting the activities of these critical signaling 
kinases. Treatment with MMS failed to induce a significant 
increase in RECQ1 mRNA when the ATM or DNA-PK 
activity was inhibited (Figure 1D) indicating that both 
ATM and DNA-PK contribute to the observed RECQ1 
upregulation following MMS induced genotoxic stress. 
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DNA damage induced upregulation in RECQ1 
expression is p53-dependent
The tumor suppressor p53 functions as a master 
transcriptional regulator of cellular responses to genotoxic 
stress by inducing cell cycle arrest or apoptosis [35]. To 
test whether p53 is involved in RECQ1 upregulation, we 
analyzed the MMS-triggered induction of RECQ1 mRNA 
in isogenic colon cancer cell lines proficient or deficient for 
p53. Treatment of p53-proficient HCT116 cells with MMS 
(4 h) resulted in a dose dependent increase in RECQ1 
mRNA (Figure 2A) as measured by qRT-PCR using two 
independent primer sets; in contrast, no significant change 
in β-actin mRNA was observed in response to MMS 
treatment (Figure 2A). Because we observed maximum 
induction of RECQ1 mRNA at 1 mM MMS, we chose 
this dose of MMS to compare RECQ1 mRNA levels in 
p53-proficient (p53 wild-type, p53WT) HCT116 cells and 
p53-deficient (p53 knockout, p53KO) HCT116 cells. We 
found that RECQ1 mRNA was induced only in p53WT-
HCT116 cells; p53KO-HCT116 cells did not upregulate 
RECQ1 up to after 8 h exposure to MMS (Figure 2B). 
As a positive control for p53-target, we also observed 
induction of p21 mRNA specifically in p53WT-HCT116 
cells. In p53WT-HCT116 cells, we observed > 10-fold 
increase in RECQ1 mRNA after 24 h of MMS treatment. 
Notably, p53KO-HCT116 cells displayed a mild (~4-fold) 
increase in RECQ1 mRNA levels at 24 h (Figure 2B). This 
induction is likely due to p53-independent stress response 
since we also observed p21 induction, as shown previously 
[36], in p53KO-HCT116 cells at 24 h treatment (Figure 
2B). Notably, this p53-dependent upregulation of RECQ1 
and p21 mRNA was also observed in p53-proficient but not 
isogenic p53-deficient RKO cells (Figure 2C). Consistent 
with the increase in RECQ1 mRNA, MMS treatment also 
resulted in a p53-dependent increase in RECQ1 protein 
in HCT116 cells (Figure 2D). Furthermore, U2OS cells 
transfected with p53 siRNA failed to upregulate RECQ1 
mRNA and the positive control p21 mRNA, following 
MMS (1 mM) treatment (Figure 2E). Collectively, these 
Figure 1: Genotoxic stress upregulates RECQ1 expression. (A) Summary of quantitative-PCR data on RECQ1 mRNA in U2OS 
cells that were either untreated or treated with etoposide (1 µM), doxorubicin (500 nM) or MMS (1 mM) for 4, 8 or 24 h. Change in β-actin 
mRNA was measured as an additional house-keeping control. (B) MMS treatment also upregulates RECQ1 in mouse embryonic fibroblasts 
(MEFs). (C) MMS induced upregulation of RECQ1 mRNA is not cell line specific and correlates with upregulation of p21, an established 
p53 target. U2OS, MCF-7, or HeLa cells were untreated or treated with MMS (1 mM) for 4 h. Fold-change in gene expression compared to 
untreated and normalized to GAPDH is shown. (D) MMS induced upregulation of RECQ1 mRNA in U2OS cells is dependent on activities 
of ATM and DNA-PK. U2OS cells were untreated or treated with pharmacological inhibitors of ATM (ATMi; 10 µM) or DNA-PK (DNA-
PKi; 10 µM) for 16 h prior to treatment with MMS (1 mM, 4 h). Fold-change in gene expression compared to untreated and normalized 
to GAPDH is shown. Values are average of three independent experiments and standard deviation is indicated by error bars. Statistical 
significance of RECQ1 expression changes in untreated versus treatment groups is indicated as *p < 0.05; #p < 0.01; **p < 0.005; ##p < 
0.001; or n. s., non-significant.
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experiments demonstrate a clear p53-dependence for 
MMS-induced upregulation of RECQ1 mRNA. 
The basal levels of RECQ1 mRNA in p53-deficient 
HCT116 and RKO cells were 0.6- and 0.8-fold as 
compared to their p53-proficient isogenic counterparts, 
indicating that basal RECQ1 expression level may also 
be p53-dependent (Supplementary Figure 1). However, 
basal RECQ1 protein levels were comparable in p53-WT 
and p53-KO HCT116 cells (Figure 4A). We also note that 
the MMS-induced upregulation of RECQ1 protein did not 
follow the same kinetics as the mRNA in p53-proficient 
HCT116 (Figure 2D). At this point, it is difficult to 
correlate the regulation at the mRNA level to the changes 
in protein levels. It is possible that RECQ1 is regulated 
both at the transcriptional and posttranscriptional levels. 
We also analyzed mRNA levels of all five human RecQ 
homologs in HCT116 and RKO cells for DNA damage and 
p53 dependence (Supplementary Figure 2). Consistent with 
Figure 2: MMS induced upregulation of RECQ1 is p53 dependent. (A) RECQ1 expression is upregulated in response to MMS 
treatment in HCT116 cells expressing wild-type p53. Cells were either untreated or treated for 4 h with the indicated dose of MMS. Fold-
change in gene expression compared to untreated and normalized to GAPDH is shown. Two primer sets (RECQ1 #1, and RECQ1 #2) were 
used for measuring RECQ1 mRNA. β-actin served as an additional housekeeping control. (B) Isogenic HCT116 cells expressing either 
the wild-type p53 (p53 WT) or knockout for p53 (p53 KO) were exposed to MMS (1 mM) for indicated time period and the fold-change 
in mRNA expression of RECQ1 and p21 compared to untreated as measured by qPCR is shown. (C) Fold-change in mRNA expression of 
RECQ1 and p21 compared to untreated in isogenic p53WT and p53KO RKO cells is shown. (D) Following treatment with MMS (1 mM) 
for indicated time, expression of RECQ1 and p53 proteins was determined by Western blot analysis of whole-cell extracts. GAPDH was 
used as a loading control and fold-change in RECQ1 protein expression normalized to GAPDH is indicated. (E) U2OS cells, 42 h after 
transfection with control siRNA or p53 siRNA, were exposed to MMS (1 mM) for indicated time period and the fold-change in mRNA 
expression of RECQ1 and p21 compared to untreated cells as measured by qPCR is shown. β-actin served as an additional housekeeping 
control. Knockdown of p53 protein level is shown by Western Blot. For all the qPCR data, values are average of three independent 
experiments and standard deviation is indicated by error bars. Statistical significance of RECQ1 expression changes in untreated versus 
treatment groups is indicated as *p < 0.05; #p < 0.01; **p < 0.005; ##p < 0.001; or n. s., non-significant.
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a previous report of transcriptional repression of RECQ4 
by p53 [37], MMS-treated p53-deficient cells displayed 
elevated RECQ4 mRNA (Supplementary Figure 2). We 
did not observe significant changes in expression of BLM 
or RECQ5 in response to MMS treatment, however WRN 
expression was upregulated in p53-dependent fashion 
(Supplementary Figure 2). In p53WT-HCT116 cells, about 
6-fold and 2-fold higher WRN mRNA was measured at 4 
and 24 h MMS treatment (1 mM) as compared to untreated 
cells. In contrast, about 4-fold and 10-fold increase 
in RECQ1 mRNA was measured at 4 and 24 h MMS 
treatment (1 mM), respectively (Supplementary Figure 2). 
Distinct kinetics and p53-dependence of RECQ1, WRN 
and RECQ4 mRNA upregulation suggests that encoded 
proteins participate at different steps and/or pathways for 
cellular response to MMS treatment. 
The RECQ1 promoter-luciferase reporter is 
responsive to p53
Having identified that MMS-induced RECQ1 
upregulation is p53-dependent, we sought to determine if 
RECQ1 is a direct target of p53. Transcription regulation 
by p53 is enacted through its binding to the consensus 
sequence motif RRRCWWGYYY(N0–13)RRRCWWGYYY 
where R is a purine, W is an adenine or thymine, Y is a 
pyrimidine and N is any base [38]. Additionally, p53 
can bind to non-canonical response elements (REs) or 
half and three-quarter consensus sequences to mediate 
transactivation of several genes including those involved 
in DNA repair responses [39]. Analysis using the 
IARC Tp53 database (http://p53.iarc.fr/TargetGenes.
aspx?&sq=p53+response+element) suggested p53-
binding sites in the RECQ1 promoter. We searched for the 
potential binding sites of p53 in a region ~1 kb upstream 
and downstream of the human RECQ1 transcriptional start 
site using Promo 3.0.2 online tool (http://alggen.lsi.upc.es/
cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) 
[40] and identified multiple putative p53-binding sites, 
majority of which are located within 819 bp upstream of 
transcription start site and 21 bp of exon 1 (Figure 3A). Of 
note, and as previously reported for p53, these predicted 
sites deviate from the consensus p53RE. To test the 
hypothesis that p53 promotes RECQ1 transcription, we 
first utilized a luciferase-reporter system employing the 
pGL3-Basic promoterless vector or pGL3-carrying a 625 
bp RECQ1 promoter fragment containing the putative p53 
binding sites and analyzed luciferase expression in the p53-
proficient and p53-deficient HCT116 cells. Our reporter 
assay also included a pGL3-p53RE that contained 11 
consensus p53 response elements as positive control [41]. 
We observed that at both 24 and 48 h after transfection, 
luciferase expression from the RECQ1 promoter-luciferase 
reporter was significantly higher in p53WT- HCT116 cells 
as compared to p53KO- HCT116 cells (Figure 3B). As a 
positive control, luciferase expression of pGL3-p53RE 
was also significantly reduced in p53KO-HCT116 cells 
whereas the luciferase activity of pGL3-empty vector 
remained comparable in p53-deficient or p53-proficient 
cells (Figure 3B). This data indicates that basal RECQ1 
promoter activity is driven by p53 and is consistent with 
our data showing that endogenous basal RECQ1 mRNA 
levels are higher in p53WT-HCT116 cells as compared to 
p53KO-HCT116 cells (Supplementary Figure 1). 
DNA damage recruits p53 to the RECQ1 
promoter 
We next employed chromatin immunoprecipitation 
(ChIP) experiments in conjunction with qPCR to 
determine if endogenous p53 associates with the 
predicted binding sites in the RECQ1 promoter. Cross-
linked chromatin from p53-proficient or p53-deficient 
HCT116 cells, untreated or treated with MMS (1 mM, 8 
h) was immunoprecipitated with a control IgG or specific 
antibody against p53 (DO-1). Following cross-link 
reversal, the immunoprecipitated chromatin was subjected 
to qPCR to determine the enrichment of RECQ1-promoter 
sequence using three independent primer sets spanning 
the predicted p53 binding sites within RECQ1 promoter. 
In untreated p53WT- HCT116 cells, we found ~2-fold 
enrichment of p53 at the RECQ1 promoter containing 
putative p53 binding sequences (Figure 3C). Treatment 
with MMS resulted in a marked increase in p53 binding 
at the RECQ1 promoter; we observed ~3-, 7-, and 11-fold 
enrichment in p53 binding at RECQ1 promoter site 1, 2 
and 3, respectively in p53WT-HCT116 cells (Figure 3C). 
As a positive control for the p53-ChIP assay, we confirmed 
p53 binding to a known p53RE of p21 [41], a downstream 
target of p53, in p53WT-HCT116 cells (Figure 3C). MMS 
treatment also resulted in 6-fold enrichment of p53 at 
the p21 promoter as compared to 2-fold enrichment in 
untreated p53WT- HCT116 cells (Figure 3C). In contrast, 
the RECQ1 promoter or the p21 promoter was not 
enriched in the p53-ChIP material in p53KO-HCT116 cells 
indicating that the observed enrichment of the RECQ1 and 
p21 promoter in the p53-ChIP material in HCT116-p53WT 
cells was specific to p53 (Figure 3C, 3D). In untreated or 
MMS-treated condition, we did not observe enrichment 
of a negative control genomic region corresponding to 
GAPDH in the p53-ChIP over IgG-ChIP, (Figure 3C, 3D) 
demonstrating specificity of the interaction between p53 
and the p53-response elements in the RECQ1 promoter. 
Chromatin immunoprecipitation with RNA polymerase 
(Pol) II antibody demonstrated a p53-dependent and 
significantly enhanced recruitment of RNA Pol II to 
the promoter regions of RECQ1 and p21 upon MMS 
treatment suggesting transcriptional upregulation 
(Figure 3E). Binding of p53 to the RECQ1 promoter 
and the enhanced binding following MMS treatment 
was also observed in U2OS cells (Supplementary Figure 
3A). We also observed binding in these regions of the 
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Figure 3: p53 is enriched at the RECQ1 promoter following MMS treatment. (A) Partial sequence of the RECQ1 promoter 
(−819 bp to +21 bp) is shown with potential p53-binding sites predicted by Promo 3.0.2 indicated in red, those predicted by Tp53 database 
are underlined, and those predicted by both Promo 3.0.2 and Tp53 are indicated in bold. Transcriptional start site is indicated as +1.  The 
position of primer used for PCR-cloning of a 625 bp fragment from RECQ1 promoter in pGL3-Basic for luciferase assay is indicated by 
blue arrow. Three primer sets used for ChIP-qPCR analyses of p53 binding are indicated. (B) Dual Luciferase Assay shows p53-dependent 
transcriptional activation of a 625bp fragment from RECQ1 promoter region; pGL3_p53RE served as a positive control and pGL3_vector 
as a negative control. The relative luciferase activity was first determined by ratio of firefly and renilla luciferase activity for each sample 
in p53-WT and p53-KO HCT116 cells, and the relative promoter activity in p53-KO was calculated using the relative luciferase activity 
from p53-WT cells transfected by each pGL3-basic construct as a reference of 1. Bars indicate mean values plus standard deviation of 
three independent experiments. (C) MMS-induced enrichment of p53 to RECQ1 promoter. HCT116 cells, p53-WT or p53-KO, untreated or 
treated with MMS (1 mM, 8 h), were processed for ChIP using a p53-specific antibody. ChIP experiments with rabbit IgG served as negative 
control. ChIP-qPCR of immunoprecipitated DNA with three probes specific for RECQ1 promoter sequence containing predicted p53 binding 
sites (#1, #2, and #3, and as shown in A). Binding of p53 to p21 promoter containing p53RE served as a positive control. Fold enrichment 
over IgG was determined and is shown for each primer pair for the ChIP. Relative occupancy at RECQ1 and p21 promoter sequence versus 
a negative control site DNA containing GAPDH shows MMS treatment induced enrichment of p53. Statistical significance of enrichment 
in untreated versus treatment groups is indicated. Results are expressed as means ± SEM for at least three independent experiments. (D) A 
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RECQ1 promoter corresponding to the p53 ChIP-seq 
peak in data from U2OS cells published by others [42] 
(Supplementary Figure 3B–3D). Our results suggest in 
vivo association of p53 with RECQ1 promoter is enriched 
upon MMS-induced DNA damage. Overall, the presence 
of p53 binding site, and the observed MMS-induced 
enrichment of p53 at the RECQ1 promoter is consistent 
with the hypothesis that p53 mediates the upregulation of 
RECQ1 after DNA damage. 
RECQ1 promotes DNA repair and survival 
following MMS-treatment
Given the well-established roles of p53 in genotoxic 
stress response, we sought to determine the effect of 
RECQ1-depletion in p53-proficient and p53-deficient 
HCT116 cells on survival after MMS treatment. We 
transfected these cells with a control (CTL) siRNA 
or RECQ1 siRNAs (20 nM) for 48 h and validated 
significant knockdown of RECQ1 protein (> 90%) 
by immunoblotting (Figure 4A). Following 48 h of 
transfection, CTL or RECQ1 siRNA-transfected cells 
were exposed to increasing concentrations of MMS for 24 
h and cell survival was measured by trypan blue exclusion 
assay following a 24 h recovery in drug free medium 
(Figure 4B). As reported previously [43], p53KO-HCT116 
cells were more sensitive to MMS treatment than p53WT-
HCT116 cells. As compared to CTL siRNA transfected 
cells, RECQ1-depletion in p53WT-HCT116 cells also 
resulted in increased MMS sensitivity; however, RECQ1-
depletion in p53KO-HCT116 cells caused maximum 
sensitivity to MMS (Figure 4B). This synergistic effect on 
survival upon concurrent deficiency of RECQ1 and p53 
indicates their parallel roles in DNA damage response 
to MMS. It is also likely that compensatory mechanisms 
operate in the combined absence of RECQ1 and p53 since 
the depletion of RECQ1 in p53-KO cells did not show a 
dramatic reduction in survival.
Similar to our observation in HCT116 cells, U2OS 
cells stably transduced with a RECQ1 shRNA were more 
sensitive than those transduced with a CTL (luciferase)-
shRNA over a range of MMS concentration tested 
(Figure 4C). This data demonstrates that the increased 
sensitivity to MMS is not cell-type specific and is 
sustained in cells depleted of RECQ1 over a longer period 
of time. MMS is known to produce heat-labile DNA 
damage repaired by base excision repair, but no detectable 
in vivo DNA double strand breaks [44]. DNA alkylation 
due to MMS also blocks replication fork elongation in 
mammalian cells, causing formation of replication-
associated DNA lesions [45]. The cellular level of RECQ1 
protein modulates overall DNA damage [22] and RECQ1 
functions in replication restart following stress [25]. Thus, 
we next examined γH2AX as a surrogate marker of DNA 
double strand breaks in CTL and RECQ1-knockdown 
U2OS cells exposed to MMS (1 mM, 4h) or Doxorubicin 
(1 µM, 4 h), a topoisomerase II-stabilizing drug known 
to cause double strand breaks in DNA [46]. At the 
protein level, increased RECQ1 levels were observed 
in control U2OS cells upon treatment with MMS and 
doxorubicin (Figure 4D); and this increase was more 
readily noticeable in short exposure due to constitutively 
high abundance of RECQ1 protein in total cell lysate 
used in Western Blots. The increased RECQ1 protein 
is consistent with the observed upregulation of RECQ1 
mRNA in U2OS cells (Figure 1A). In control U2OS 
cells, MMS treatment did not result in significant double 
strand breaks as detected by γH2AX signal. In contrast, 
RECQ1-knockdown U2OS cells demonstrated greater 
γH2AX signal after treatment with MMS (Figure 4D). 
As compared to control U2OS cells, RECQ1-knockdown 
cells also exhibited significantly greater γH2AX 
after doxorubicin treatment (Figure 4D). As reported 
previously [46], doxorubicin treatment stabilized p53 and 
increased p21 levels indicating transcriptional activation; 
RECQ1-knockdown cells displayed greater signal for 
p53 and p21 proteins as compared to control U2OS cells 
(Figure 4D). Since γH2AX is formed in response to direct 
or indirectly-produced double strand breaks, the presence 
of double strand breaks was also measured using a neutral 
comet assay. We determined tail moment, a measure of 
the amount and distance of DNA migration, in control 
and RECQ1-knockdown U2OS cells. As compared to 
untreated condition, treatment with Doxorubicin (1 µM, 
4 h) or MMS (1 mM, 4 h) resulted in increased tail 
moment in U2OS cells (Figure 4E). Consistent with the 
observed increase in γH2AX, RECQ1-knockdown U2OS 
cells exhibited increased mean tail moment as compared 
to control U2OS cells, indicating higher levels of double 
strand breaks when exposed to doxorubicin or MMS in 
neutral comet assays (Figure 4E).
Overall, increased accumulation and transactivation 
of p53, and increased double strand breaks are consistent 
with the observed sensitivity of RECQ1-deficienct cells 
to MMS as shown here and doxorubicin as recently 
reported [47]. 
representative agarose gel of the amplified DNA immunoprecipitated with p53 antibody shows MMS-induced enrichment of p53 to RECQ1 
promoter whereas MMS treatment did not change GAPDH abundance in p53 ChIP. M, DNA size marker. (E) Enhanced recruitment of 
RNA POL II to RECQ1 promoter following MMS treatment. HCT116 cells, p53-WT or p53-KO, untreated or treated with MMS (1 mM, 
8 h), were processed for ChIP using a RNA POL II-specific antibody or rabbit IgG. Binding of RNA POL II to RECQ1 promoter sequence 
and p21 promoter was measured by qPCR of immunoprecipitated DNA. Fold enrichment over IgG was determined and is shown for each 
primer pair for the ChIP. Relative occupancy at RECQ1 and p21 promoter sequence versus a negative control non-promoter GAPDH 
sequence shows MMS treatment induced enrichment of RNA POL II. Statistical significance of enrichment in untreated versus treatment 
groups is indicated. Results are expressed as means ± SEM for at least three independent experiments.
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RECQ1 expression positively correlates with 
cellular resistance to clinically relevant DNA 
damaging agents
RECQ1 deficiency leads to genomic instability 
and sensitivity to a range of genotoxins [4, 5]. Given the 
sensitivity of RECQ1-deficient cells to MMS, we first 
examined whether RECQ1 expression is upregulated at 
the mRNA level after treatment with clinically relevant 
alkylating agents Temozolomide (TMZ) and Fotemustine 
(FMS), both of which are used as cancer chemotherapeutics 
[48]. Following 8 h treatment of p53WT-HCT116 cells 
with TMZ, > 4-fold and 6-fold increase in RECQ1 mRNA 
was observed in cells treated with 0.5 mM and 1 mM 
TMZ, respectively (Figure 5A). Treatment with FMS 
also upregulated RECQ1 mRNA in HCT116 cells, and 
a comparable increase (> 4-fold) in RECQ1 mRNA was 
observed after 8 h treatment with 32 µM or 64 µM FMS 
(Figure 5B). As observed for the MMS sensitivity, p53KO-
HCT116 cells were more sensitive for TMZ and RECQ1-
depletion led to increased sensitivity in both p53-proficient 
and p53-deficient HCT116 cells (Figure 5C). Moreover, 
treatment with TMZ (1 mM, 8 h) or FMS (32 µM, 8 h) also 
upregulated RECQ1 mRNA in U2OS cells (Figure 5D); and 
RECQ1-knockdown cells were more sensitive than control 
U2OS cells over a range of TMZ and FMS concentration 
tested (Figure 5E, 5F). Presence of TMZ (100 µM, 5 days) in 
growth medium resulted in increased RECQ1 protein level 
Figure 4: RECQ1 promotes DNA repair and survival after MMS treatment. (A) Western blot showing siRNA knockdown 
of RECQ1 in p53-proficient and p53-deficient HCT116 cells. (B) RECQ1-depletion and p53 loss have synergistic effect on survival. 
Following 48 h of siRNA transfection, p53WT and p53KO-HCT116 cells were exposed to MMS for 24 h and subsequently grown for 24 
h in drug-free medium. Surviving fraction compared to untreated was determined by cell count. Knockdown of RECQ1 was confirmed by 
Western blotting as shown. (C) U2OS cells stably transduced with a control (shCTL) or RECQ1 (shRECQ1)-specific shRNA were exposed 
to MMS for 24 h and subsequently grown for 24 h in drug-free medium. Surviving fraction compared to untreated was determined by cell 
count. (D) Western blot analysis of whole cell extracts of stable control and RECQ1 knockdown U2OS cells, untreated or treated with 
doxorubicin (1 µM) or MMS (1 mM) for 4 h. A short exposure of RECQ1 Western blot is also included. (E) DNA double strand breaks in 
control or RECQ1-depleted cells. Neutral Comet Assay was used to determine tail moment as a measure of double strand breaks in stable 
control and RECQ1 knockdown U2OS cells, untreated or treated with doxorubicin (1 µM) or MMS (1 mM) for 4 h. Mean tail moment of 
untreated shCTL was used to normalize the data and is shown as 100%. Statistical significance of difference in tail moment as compared to 
untreated shCTL is indicated as *p < 0.05; #p < 0.01; **p < 0.005 or n. s., non-significant.
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in control U2OS and MCF7 cells, and led to cleaved PARP 
in RECQ1 knockdown U2OS and MCF7 cells indicating 
enhanced apoptosis (Figure 5G). These results collectively 
demonstrate that DNA alkylating agents including the 
laboratory agent MMS and chemotherapeutics TMZ or 
FMS induce upregulation of RECQ1 mRNA, and RECQ1 
expression level correlates with cellular sensitivity to these 
treatments. As compared to control untreated U2OS cells, 
RECQ1 mRNA was also upregulated following treatment 
with chemotherapeutics 5-fluoro uracil (5-FU), gemcitabine, 
camptothecin as well as the laboratory carcinogen 
methylnitronitrosoguanidine (MNNG) and environmental 
mutagen benzo[a]pyrene (Supplementary Figure 4). This is 
consistent with previous studies where RECQ1-depletion 
increased cellular sensitivity to camptothecin and benzo[a]
pyrene [22, 49].
Figure 5: RECQ1 expression is upregulated by the chemotherapeutic drugs that alkylate DNA and positively 
correlates with cellular resistance to these treatments. (A, B) RECQ1 expression is upregulated in response to Temozolomide 
(TMZ) or Fotemustine (FMS) treatment of HCT116 cells expressing wild-type p53. RECQ1 mRNA expression was measured using two 
independent primer sets; fold-change in expression compared to untreated and normalized to GAPDH is shown. β-actin served as an 
additional housekeeping control. Values are average of three independent experiments and standard deviation is indicated by error bars. 
Statistical significance of RECQ1 expression changes in untreated versus treatment groups is indicated as *p < 0.05; #p < 0.01; **p < 0.005; 
##p < 0.001; or n. s., non-significant. (C) Following 48 h of control or RECQ1 siRNA transfection, p53WT and p53KO-HCT116 cells 
were exposed to increasing dose of TMZ for 24 h and subsequently grown for 24 h in drug-free medium. Surviving fraction compared to 
untreated was determined by cell count. Knockdown of RECQ1 was confirmed by Western blotting (not shown). Surviving fraction values 
are the mean ± SEM from three independent experiments. (D) RECQ1 expression is also upregulated in U2OS cells following treatment 
with TMZ (1 mM, 6 h) or FMS (32 µM, 6 h). Fold-change in expression compared to untreated and normalized to GAPDH is shown. Values 
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Genotoxic stress-induced upregulation of RECQ1 
mRNA expression in MDA-MB-231 cells 
p53 is a well-known tumor suppressor and p53 
mutations are by far the most common in human cancer, 
including breast cancer.  MDA-MB-231 human breast 
cancer cells express mutant p53 (p53R280K) that confers 
a “gain of function” including chemotherapy resistance, 
metabolic deregulation, and increased metastasis.  Unlike 
wild-type p53 that primarily mediates its effects through 
sequence-specific DNA binding to cognate p53 response 
elements located in the promoters of p53 target genes, the 
mutant p53 protein generally has diminished wild-type p53 
activity but it regulates gene expression via interactions 
with other transcription factors [50–53]. Interestingly, 
we found that DNA damage also upregulated RECQ1 
mRNA in MDA-MB-231 cells (Figure 6A).  To determine 
whether mutant p53 affected the expression of RECQ1, 
we utilized the CRISPR/Cas9 technology to knockout 
mutant p53 in MDA-MB-231 cells (Supplementary 
Figure 5). After confirming successful targeted deletion 
by Sanger sequencing (data not shown), we performed 
immunoblotting. As shown in Figure 6B, mutant p53 
protein was lost in the knockout clone (p53_KO#1) but it 
was robustly expressed in an isogenic clone in which the 
mutant p53 gene was intact (mutp53).  MMS treatment 
resulted in a 5-fold increase in RECQ1 mRNA in the 
mutp53-expressing clone whereas no significant change 
in RECQ1 mRNA was observed in p53_KO#1 clone 
(Figure 6C). Furthermore, p53-ChIP in MDA-MB-231 cells 
recovered RECQ1 promoter regions indicating that mutant 
p53 associates with the RECQ1 promoter (Figure 6D). 
These data indicate that RECQ1 mRNA is induced by 
DNA damage in a mutant p53-dependent manner in MDA-
MB-231 cells.  
Clinical correlation of RECQ1 expression in 
human cancer
Germline mutations in RECQ1 significantly enhance 
lifetime risk of developing breast cancer [9, 10]. In the 
Cancer Genome Atlas (TCGA), out of 817 patients 
analyzed for the Breast Invasive Carcinoma [54], 68 
samples showed RECQ1 mRNA upregulation whereas only 
7 showed downregulated RECQ1 mRNA. In addition, the 
RECQ1 gene is affected also by copy number alterations, 
with 3 patients showing a deep deletion and 17 patients 
showing an amplification of which 14 also showed RECQ1 
overexpression (Supplementary Figure 6A). In this dataset, 
carriers of altered RECQ1 copy number and mRNA 
expression show a significantly shorter overall survival 
(Supplementary Figure 6B). Analysis of TCGA data 
shows significant association of RECQ1 alterations with 
p53 mutation (p < 0.001). Similarly, RECQ1 alterations 
exhibit significant tendency to co-occur with p53 mutations 
in METABRIC cohort of breast cancer patients where 
RECQ1 expression is correlated with patient survival [47]. 
To investigate whether RECQ1 mRNA expression predicts 
response to chemotherapy, we explored a large gene 
expression data set of 3951 human breast tumors (http://
kmplot.com/analysis/index.php?p=service&default=true) 
[55]. In the whole cohort that received chemotherapy, 
high RECQ1 mRNA was associated with poor survival 
(Figure 7B) (p = 0.00005). In patients who received no 
chemotherapy, high RECQ1 mRNA was also associated 
with poor survival (Figure 7A), but this association was 
less significant (p = 0.022). In p53 wild-type tumors, 
high RECQ1 mRNA was associated with poor survival 
in patients who received no chemotherapy (Figure 7C) 
(p = 0.027) and was borderline non-significant in patients 
who received chemotherapy (Figure 7D) (p = 0.085). 
These data may be consistent with our result from cell lines 
where we found that in p53 wild-type cells, knockdown of 
RECQ1 results in increased sensitivity to DNA damage. 
Interestingly in p53 mutant tumors, we observed the 
opposite. Low RECQ1 mRNA was significantly associated 
with poor survival in patients who received chemotherapy 
(Figure 7F) (p = 0.004) and was borderline non-significant 
in patients who received no chemotherapy (Figure 7E) 
(p = 0.072). Taken together, these clinical data suggest 
that the prognostic and predictive significance of RECQ1 
expression may be influenced by p53 status in breast 
cancers.
DISCUSSION
Our results demonstrate upregulation of endogenous 
RECQ1 upon exposure to DNA damaging agents. We 
found that the DNA damage induced upregulation of 
RECQ1 mRNA is p53-dependent which binds and activates 
the RECQ1 promoter. We demonstrate that induction 
of RECQ1 by DNA damage occurs in p53-proficient 
HCT116 cells at the level of mRNA and protein. RECQ1 
expression is also upregulated in cells exposed to TMZ, 
FMS, and doxorubicin; and correlates positively with cell 
survival following treatment with these agents. Induction of 
are average of three independent experiments and standard deviation is indicated by error bars. Statistical significance of change in RECQ1 
expression compared to untreated is indicated. (E, F) Stable control (shCTL) and RECQ1 knockdown (shRECQ1) U2OS cells were 
exposed to increasing dose of TMZ or FMS for 24 h and subsequently grown for a further 24 h in drug-free medium. The graphs show the 
cellular surviving fractions measured at different doses of drug treatment in control and RECQ1-depleted cells. Surviving fraction values 
are the mean ± SEM from three independent experiments. (G) Whole cell extracts prepared from stable control and RECQ1 knockdown 
U2OS and MCF7 cells cultured for 5 days in the absence or presence of TMZ (100 µM) were subjected to Western blot analysis of cleaved 
PARP for apoptosis. Knockdown of RECQ1 was verified by Western blotting. TMZ treatment lead to increase in RECQ1 protein level in 
both U2OS and MCF7 cells transduced with control shRNA.
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RECQ1 mRNA by genotoxins was seen in osteosarcoma, 
breast cancer, and colon cancer cell lines. Our observation 
that mouse embryonic fibroblasts also upregulated RECQ1 
expression in response to DNA damage is consistent with 
its DNA repair function and suggests that RECQ1 may 
protect normal cells from the DNA damaging effects of 
anticancer drugs. Upregulation of RECQ1 expression in 
cancer cells, however, may contribute to chemoresistance. 
Our findings are consistent with a previous proteome-wide 
study where etoposide treatment increased the abundance 
of RECQ1 peptides specifically in p53-proficient cells 
but not in p53-deficient cells [56]. This is the first report 
of RECQ1 as being p53-regulated transcriptional target, 
although a distinct role for RECQ1 has been described 
in the maintenance of the genomic stability [57]. RECQ1 
catalyzes DNA unwinding and strand annealing [58], and 
Figure 6: DNA damage induced upregulation of RECQ1 expression in MDA-MB-231 cells expressing mutant p53. 
(A) RNA was isolated from MDA-MB-231 cells that were untreated or treated with MMS (1 mM), doxorubicin (1 µM), gemcitabine (2 
µM) or camptothecin (1 µM) as indicated. Fold-change in RECQ1 mRNA expression compared to untreated and normalized to GAPDH is 
shown. SDHA served as an additional housekeeping control. Values are average of three independent experiments and standard deviation 
is indicated by error bars. Statistical significance of change in RECQ1 expression compared to untreated is indicated. (B) Western Blots 
showing loss of p53 protein in TP53 knockout (p53_KO#1) MDA-MB-231 clone and another clone with unchanged level of p53 (mutp53). 
GAPDH was used as a loading control. (C) Isogenic MDA-MB-231 cells expressing with the mutant p53 (mutp53) or knockout for p53 
(p53_KO#1) were exposed to MMS (1 mM) for 8 h and the fold-change in mRNA expression of RECQ1 and β-actin compared to untreated 
and normalized to GAPDH is shown. Statistical significance of change in RECQ1 expression compared to untreated mup53 is indicated. 
(D) MMS-induced enrichment of mutant p53 to RECQ1 promoter in MDA-MB-231 cells. MDA-MB-231 cells, untreated or treated with 
MMS (1 mM, 8 h), were processed for ChIP using a p53-specific antibody. ChIP experiments with rabbit IgG served as negative control. 
ChIP-qPCR of immunoprecipitated DNA with primers specific for RECQ1 promoter sequence containing predicted p53 binding sites 
(#1 and #2, as shown in 3A) was performed. Fold enrichment over IgG was determined and is shown for each primer pair for the ChIP. 
Statistical significance of enrichment in untreated versus treatment groups is presented. Results are expressed as means ± SEM for at least 
three independent experiments.
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these activities are likely to be important for its role in 
DNA repair [8]. Together our findings significantly expand 
on prior observation and indicate that transcriptional 
regulation of RECQ1 is potentially involved in an adaptive 
and/or a protective response to genotoxic stress. 
Standard chemotherapy for cancer aims to produce 
replication stress induced DNA damage thereby promoting 
death preferentially in rapidly proliferating cancer 
cells. However, the ability of cancer cells to recognize 
this damage and initiate DNA repair is an important 
mechanism for drug resistance and poor therapeutic 
efficacy [1]. Genetic variations such as mutations, copy 
number changes, change in mRNA expression, or single 
nucleotide polymorphisms in DNA repair genes may 
encode alterations that affect DNA repair function and, 
therefore, influence individual’s risk of cancer development 
Figure 7: Clinical correlation of RECQ1 expression with p53 status for survival outcomes in breast cancer. Kaplan-
Meier curves correlating RECQ1 mRNA expression and relapse free survival in breast cancer patients from kmplotter.com are shown. (A, 
B) Survival of patients, in the whole cohort of 3951 breast tumors, who received no chemotherapy (A) or did receive chemotherapy (B). 
(C, D) Survival curves for patients with wild-type p53 who received no chemotherapy (C) or received chemotherapy (D). (E, F) Survival 
curves for patients with mutant p53 who received no chemotherapy (E) or received chemotherapy (F).
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and clinical response to cytotoxic therapies [1, 2]. A 
polymorphism in RECQ1, A159C located in the 3′UTR, is 
associated with faster tumor progression and significantly 
reduced survival of pancreatic adenocarcinoma patients 
who received gemcitabine and radiotherapy [16]. 
Gemcitabine, a nucleoside analog, disrupts DNA replication 
and interferes with the homologous recombination repair of 
DNA, whereas RECQ1 helicase functions are important to 
restore productive DNA replication [8]. It is possible that 
the A159C variant allele confers higher RECQ1 expression, 
leading to a better repair of the gemcitabine-induced DNA 
damage and, hence, a poor clinical response. In oral 
squamous cell carcinoma, RECQ1 expression correlated 
with cisplatin resistance [59] and RECQ1-depletion 
significantly augmented the in vivo anticancer effects of 
the drug cis-platinum (II) diammine dichloride that induce 
inter-strand cross links in DNA to impair progression of 
replication forks [19]. In sporadic ER- negative breast 
tumors, high RECQ1 expression is associated with poor 
survival in patients that received anthracycline based 
chemotherapy; and RECQ1-depletion in breast cancer 
cells increased doxorubicin chemosensitivity owing to 
DNA double strand breaks accumulation, S-phase cell cycle 
arrest and apoptosis [47]. Viziteu et al. recently reported 
that RecQ helicases are deregulated in hematological 
malignancies compared to their normal counterparts and 
expression of RECQ1 was associated with significantly 
poor survival [60]. In a subsequent study, RECQ1 
overexpression in multiple myeloma cells conferred 
resistance against the DNA alkylating drug melphalan 
and proteasome inhibitor bortezomib, and high expression 
of RECQ1 associated with poor prognosis in multiple 
myeloma patients treated with high dose melphalan [61]. 
Noteworthy, RECQ1 was significantly overexpressed in 
patients with deletion of chromosome 17p which harbors 
TP53, suggesting that additional factors may regulate 
RECQ1 expression [61]. Observed sensitivity of RECQ1-
depleted cells to DNA alkylating agents is consistent with a 
newly identified role of RECQ1 in BER [31] and a previous 
study where glioblastoma cells depleted of RECQ1 were 
found to be more sensitive to TMZ treatment [62]. Indeed, 
deficiency of a BER factor or imbalance in BER enzymatic 
steps contribute to sensitizing cells to killing effects of 
alkylating agents [63]. A mechanism to tolerate alkylating 
adducts is through the activities of translesion DNA 
polymerases [3]. However, unrepaired DNA adducts in 
such cases interfere with replication fork progression giving 
rise to secondary DNA damage including strand breaks 
[44]. RECQ1 through the repair of stalled replication forks 
at sites of alkylated bases and its role in BER may serve to 
prevent chromosome breakage upon exogenous replication 
stress and DNA damage induced by alkylating agents. 
It is yet unclear how the missense mutations that 
disrupt RECQ1 enzymatic activities and altered (mostly 
increased) RECQ1 expression will impact breast cancer 
prognosis. A survey of Oncomine reveals that RECQ1 
is overexpressed and amplified in many clinical cancer 
samples versus normal samples [27, 64]. In human cells, 
RECQ1 is ranked amongst the top 5–25% most abundant 
proteins in Protein Abundance Database, PaxDb [65]. It 
can be reasoned that even a 2-fold increase in the basal 
level of RECQ1 protein in cells that already express it at 
significantly high level will likely enhance cellular capacity 
of DNA repair following DNA damage. Given the roles 
of RECQ1 in resolving replication stress, our results 
suggest that RECQ1 overexpression could be a marker of 
chemoresistance and DNA damage induced upregulation 
of RECQ1 would be especially important for survival 
of highly proliferative cancer cells. Targeted inhibition 
of RECQ1 expression or pharmacological inhibition of 
RECQ1 enzymatic activity could potentially enhance 
therapeutic action of anticancer drugs in p53-deficient 
tumor cells that are much more reliant than normal cells 
on pathways that resolve replication stress. Although we 
found that RECQ1 mRNA is induced upon DNA damage 
in the mutant p53-expressing MDA-MB-231 cells and 
this induction is lost upon targeted deletion of mutant 
p53, future studies are needed to determine if this is also 
observed in a panel of cell lines that express gain-of-
function mutant p53 proteins. Given the established role 
of RECQ1 in DNA repair, it will be interesting to examine 
if the enhanced chemoresistance of mutant p53-expressing 
cells is mediated, in part, via induction of RECQ1.   
Our demonstration that RECQ1 is a p53-responsive 
gene in the context of genotoxic stress suggests that a 
RECQ1 inhibitor may be beneficial to cancer patients 
who retain wild-type p53. Notably, and despite significant 
sequence conservation among the RecQ family members, 
specific inhibitors of WRN and BLM helicases have 
been developed [66, 67]. RECQ1 knockout animals are 
phenotypically normal [21], indicating that the RECQ1 
helicase is not a general regulator of cellular proliferation 
and aberrant expression in cancer may be acquired on 
cellular transformation, suggesting targeting RECQ1 could 
be potentially tumor specific. The p53 tumor suppressor 
protein is critical in orchestrating the genomic response 
to stress by transcriptional regulation of genes involved 
in key cellular processes such as DNA repair, cell cycle 
arrest, senescence and apoptosis. It would be interesting to 
test, in future, whether concurrent p53 loss will expose the 
deleterious effects of genetic knockout of RECQ1 in mice 
which might otherwise be compensated in a p53-proficient 
background. Given the recent associations of RECQ1 
mutations and expression with cancer susceptibility and 
response to therapy, it will be important to understand the 
roles of RECQ1 in the context of other relevant and known 
susceptibility genes in tumor biology. 
In summary, our findings illustrate previously 
unknown regulation of RECQ1 expression in response 
to DNA damage and may be useful in understanding 
the clinical significance of RECQ1 expression in tumor 
development and therapeutic response. Identification of 
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synergistic genes and pathways, and characterization of 
regulatory mechanisms for RECQ1 expression through 
the functional studies may instruct alternative therapeutic 
strategies. 
MATERIALS AND METHODS
Cell culture and DNA damage treatments
Isogenic pair of p53-wild type (p53WT) and p53-
knockout (p53KO) human colon carcinoma cell lines 
HCT116 and RKO were provided by Dr. B. Vogelstein 
(The Johns Hopkins Kimmel Cancer Center, Baltimore, 
MD); human cervical adenocarcinoma HeLa, osteosarcoma 
U2OS and breast adenocarcinoma MCF7 and MDA-
MB-231 cell lines used in this study were purchased from 
American Type cell culture (ATCC); and mouse embryonic 
fibroblasts (MEFs) have been described [21]. Cells were 
maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum (FBS). All 
cells were cultured in a humidified atmosphere containing 
5% CO2 at 37°C and routinely checked for mycoplasma 
contamination using a PCR based assay (Sigma, catalog 
no. MP0035). MMS, TMZ, FMS, doxorubicin, etoposide, 
camptothecin, gemcitabine, MNNG, 5-FU, and benzo[a]
pyrene, were purchased from Sigma; inhibitors for ATM 
(Ku55933) and DNA-PK (Nu7026) were purchased from 
Selleck Chemicals. All stock solutions were made as 
recommended by the vendors and used for treatment of 
cells in culture. 
RNAi mediated knockdown of RECQ1 and p53
On-Target plus SMARTpool small interfering 
RNAs (siRNAs) against RECQ1 or p53 and control 
siRNAs were purchased from Dharmacon. All siRNA 
transfections were performed by reverse transfection 
at a final concentration of 20 nM using Lipofectamine 
RNAiMAX (Invitrogen) as instructed by the manufacturer. 
Stable shRNA-mediated knockdown of RECQ1 in U2OS 
cells was achieved using a lentiviral system [25]. Briefly, 
lentivirus particles were produced by cotransfecting 
293T cells with the pLKO.1 lentiviral shRNA expression 
vector containing the RECQ1 targeting sequence 
(5′-GAGCTTATGTTACCAGTTA-3′) or the gene encoding 
Luciferase (5′-ACGCTGAGTACTTCGAAATGT-3′) 
with the packaging plasmids psPAX2 and pM2D.G; and 
used to transduce U2OS cells, followed by selection with 
puromycin (2.5 µg/ml). 
Generation of TP53 knockout MDA-MB-231 
clones
CRISPR-mediated TP53 knockout MDA-MB-231 
cells were generated using an all-in-one pD1401-AD 
plasmid expressing the Cas9 nickase (Cas9-D10A), 
GFP and the 2 gRNAs targeting the TP53 exon that was 
common to all p53 mRNA isoforms (Supplemental figure 
5). MDA-MB-231 cells were transfected with 1 μg of 
plasmid by Nucleofection using Amaxa® Nucleofector® 
Kit V (Catalog # VCA-1003). After 48 h, transfected 
cells were GFP sorted and seeded at one cell per well in 
96-well plates containing DMEM. Single colonies were 
expanded and protein was extracted using RIPA buffer. 
Knockout clones were genotyped by Sanger sequencing 
and p53 loss was confirmed by immunoblotting using 
an Anti-p53 antibody (DO1, Santa Cruz catalog 
number sc-126). gRNAs sequences targeting TP53: 
gRNA1- GATGGCCATGGCGCGGACGC; gRNA2- 
GCAGTCACAGCACATGACGG. 
Preparation of RNA and qRT-PCR
Total RNA was extracted from cells using Trizol (Life 
Technologies). The quantification of the extracted RNA 
was done using a NanoDrop 2000c Spectrophotometer 
(Thermo Scientific). For quantitative reverse transcription-
PCR (RT-qPCR) analysis, 500 ng of total RNA was reverse 
transcribed using the iScript RT kit (Bio-Rad), and qPCR 
was performed using SYBR green (Bio-Rad) as directed 
by manufacturer. The glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and β-Actin housekeeper genes 
were used as internal control. The qPCR for each RNA 
sample was performed in triplicate. No template control 
was used to rule out cross contamination of reagents and 
a RT minus control was used to rule out genomic DNA 
contamination. Statistical significance of gene expression 
changes in untreated versus treatment groups was confirmed 
using a two-tailed paired Student-t test and is presented in 
the figures as *p < 0.05; #p < 0.01; **p < 0.005; ##p < 0.001; 
or n. s., non-significant. The oligonucleotide sequences of 
the primers used for qRT-PCR are as following: RECQ1 
#1 (Forward: 5′-CAATGGCTGGAAAGGAGGTA-3′; 
Reverse: 5′-AATGGGCAAATGACGAGTGT-3′), RECQ1 
#2 (Forward: 5′-TGAAGCAGGCAGAGGAACTG-3′; 
Reverse: 5′-AGCCACAACACCTGCTACTC-3′); GAPDH 
(Forward: 5′-AATCCCATCACCATCTTCCA-3′; Reverse: 
5′-TGGACTCCACGACGTACTCA-3′), β-actin (Forward: 
5′-ACCAACTGGGACGAT ATGGAGAAGA-3′; Reverse: 
5′-TACGACCAGAGGCATACAGGGACAA-3′), p21 (Forward: 
5′-GACTCTCAGGGTCGAAAACG3′; Reverse: 5′-GGAT 
TAGGGCTTCCTCTTGG-3′), WRN (Forward: 5′-AATC 
TACTGAGCATTTATCTCCCA-3′; Reverse: 5′-GAGTT 
GGTTCTACCGTGCCA-3′), BLM (Forward: 5′-GAGT 
CTGCGTGCGAGGATTA-3′; Reverse: 5′-AGTGTTC 
TGGCTGAGTGACG-3′), RECQ4 (Forward: 5′-TCACAG 
TGAGGTCCCAGATT-3′; Reverse: 5′-CTGACTTCTT 
GGAAGGCTGA-3′), RECQ5 (Forward: 5′-GCTCAGG 
AAGACGGGAGAAG-3′; Reverse: 5′-AGAACAGCTT 
GGAGAACGGG-3′). Following two primer pairs were 
used for mouse: RECQ1 (Forward: 5′-GCTCTTGGCAT 
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CTTGAAGCG-3′; Reverse: 5′-CTTGAGGGCTTTTGCC 
GAAC-3′) and GAPDH (Forward: 5′-CGTGTTCCTACCC 
CCAATGT-3′; Reverse: 5′-GTGTAGCCCAAGATGCCC 
TT-3′).
Western blotting
Whole-cell lysates were prepared by using 
radioimmunoprecipitation assay (RIPA) buffer containing 
protease inhibitor cocktail (Roche), and protein was 
quantified using DC protein assay kit (Bio-Rad). 
Ten microgram of total protein per lane was used for 
immunoblotting. The following primary antibodies were 
used: anti-RECQ1 (Bethyl lab; at 1:1000 dilution); anti-p53 
(Santa Cruz Biotech, 1:2,500 dilution), anti-p21 (Santa 
Cruz Biotech, 1:500 dilution), anti-GAPDH and anti-
γH2AX (both from Cell Signaling, 1:1000 dilution). 
Chromatin immunoprecipitation assay
Cells grown at a density of 1 × 107 per 15 cm 
diameter dish, untreated or after MMS treatment (1 
mM, 8h), were used for ChIP experiments as described 
previously [68]. Following phenol/chloroform extraction 
and ethanol precipitation, sheared DNA fragments 
served as template in qPCR analysis. qPCR was performed 
using Taq Universal SYBR Green Supermix (Bio-Rad) with 
technical triplicates and threshold cycle numbers (Ct) 
were determined with an iQ5 thermal cycler (Bio-Rad). 
Fold enrichment of the targeted genomic sequences were 
calculated over IgG as: fold enrichment = 2-(CtIP− CtIgG), 
where CtIP and CtIgG are mean threshold cycles of PCR 
done in triplicates on DNA samples immunoprecipitated 
with anti-p53 (DO-1, Santa Cruz Biotech) or RNA POL II 
(CTD4H8 phospho-S5 [4H8], Abcam) antibody and control 
IgG, respectively. All qPCR reactions were also checked 
by melt curve analyses and agarose gel electrophoresis to 
confirm the presence of a single specific product. Statistical 
significance of enrichment in ChIP in untreated versus 
treatment groups was confirmed using a two-tailed paired 
Student-t test for each genomic sequence and is presented 
in the figures as *p < 0.05; #p < 0.01; **p < 0.005; 
##p < 0.001; or n. s., non-significant. Following primers 
were used: primers for -819/+21 region of RECQ1 promoter: 
#1 (Forward: 5′-TGCTTCACAGTAGCGGAAGG-3′; 
Reverse: 5′- ATGTTGGAGGAAACGCCACT-3′); #2 
(Forward: 5′-CCGGTCTTCTGATCTCCCCA-3′, Reverse: 
5′-TTAATAACGCCCGCCCTTCC-3′); #3 (Forward: 5′-T 
GCCTCTAAATGCAGGTGGC-3′; Reverse: 5′- GCA 
GGTCTGTCACTCAGCAG-3′), primer to the p21 
promoter containing p53 RE as positive control (Forward: 
5′-CTGGACTGGGCACTCTTGTC-3′; Reverse: 5′- CTC 
CTACCATCCCCTTCCTC-3′), and primers to GAPDH 




The 5′-region from −819 bp to +21 bp, relative to 
the transcription start site of RECQ1 (Gene ID 5965) 
was cloned by PCR of genomic DNA (forward primer, 
5′-AGCCAGGGACTTGTAGAGGAC-3′; reverse 
primer, 5′-TGGCGAAACCTGCTTCCAA-3′). The PCR 
product was cloned into the pGL3-Basic luciferase vector 
(Promega) using standard techniques. All constructs were 
sequence-verified. 
Luciferase reporter assay
HCT116 cells, p53-proficient or p53-deficient, at 
60% confluence in 6-well plates were co-transfected with 
500 ng pGL3-Basic luciferase reporter constructs containing 
a sequence derived from the identified p53-binding site 
upstream of the RECQ1 gene, (PGL3_RECQ1), wt p53 
binding sites (PGL3_p53RE; a gift from Bert Vogelstein 
(Addgene plasmid # 16442)[41], or empty vector and 50 
ng pRL-TK Renilla reporter (Promega) by Lipofectamine 
2000 as described by the manufacture’s protocol. Cells 
were lysed 36 h post-transfection and luciferase activity was 
measured using the Dual-Luciferase Reporter Assay System 
(Promega) according to protocol. Firefly luciferase activities 
were normalized with Renilla luciferase activities to obtain 
the relative luciferase activity. Luciferase activity for pGL3_
RECQ1 was comparable to that of pGL3_p53RE. Results 
are presented as normalized relative luciferase activity 
compared to p53-proficient HCT116 cells. 
Survival assay
Cells, seeded at a density of 3 × 103 cells per well 
in 96 well plates, were either untreated or treated with 
DNA damaging agents in complete DMEM medium as 
indicated. Cell proliferation was evaluated each day by 
trypan blue exclusion assay and counting the viable cells 
using an automated cell counter (Bio-Rad TC10). Cell 
proliferation experiments were done in triplicates in three 
independent experiments. 
Comet assay
The neutral comet assays were performed using a 
Comet Assay kit (4250-050-ESK, Trevigen) according to 
the manufacturer’s recommendations. Cells untreated or 
treated with doxorubicin (1 μM) or MMS (1 mM) for 4 h 
were trypsinized and embedded on a microscope slide in 
agarose. Slides were incubated for 30 min at 4°C in a CO2 
incubator. Cells on slides were lysed for 1 h at 4°C and 
the slides were then incubated in the dark for 30 min in 
cold neutral electrophoresis buffer prior to electrophoresis 
at 25 V for 25 min. After immersion of slides for 30 min 
each in DNA precipitation solution and 70% ethanol, DNA 
was visualized using SYBR Green I fluorescent staining. 
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Fifty cells per sample were documented in each case. 
Data was analyzed using an open-source software tool, 
OpenComet. Results are presented as normalized % tail 
moment compared to untreated control knockdown cells.
RECQ1 gene expression in human breast cancers
We initially investigated RECQ1 gene expression in 
the Breast Invasive Carcinoma TCGA cohort [54] using 
the publicly available cBioPortal for Cancer Genomics 
[69]. We then validated predictive significance of RECQ1 
in a large cohort of 3951 breast cancers [55]. Relapse 
free survival was defined as the number of months from 
diagnosis to the occurrence of local recurrence, local lymph 
node (LN) relapse or distant metastasis (DM) relapse. 
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